

Site Number: \_\_\_\_\_ Screening ID: \_\_\_\_\_ - \_\_\_\_\_

Participant Letters: \_\_\_\_\_

**Complete this form during the Baseline Visit just prior to randomization.**

**A. VISIT INFORMATION**

1. Date form completed:

\_\_\_\_/\_\_\_\_/\_\_\_\_  
DAY MONTH YEAR

**B. INCLUSION CRITERIA**

- |  |   |   |
|--|---|---|
| 1. Subject is within 3-months (100 days) of diagnosis of type 1 diabetes based on ADA criteria?  | Y | N |
| 2. Subject is between 6 and 45 years of age (inclusive)?   | Y | N |
| 3. Subject is willing to be randomized to either group assignment?   | Y | N |
| 4. Subject is willing to attend all scheduled follow-up visits at the designated clinic?   | Y | N |
| 5. Subject is willing to comply with intensive diabetes management?  | Y | N |
| 6. Subject has stimulated C-peptide levels $\geq 0.2$ pmol/ml?   | Y | N |
| 7. Subject has at least one diabetes related autoantibody? ( <i>Note: Insulin antibodies must be drawn within one-week of start of insulin therapy</i> ) | Y | N |
| 8. Subject weighs at least 20 kg (44 lb) at study entry?   | Y | N |
| 9. Subject is willing to forgo any live vaccinations during treatment and for 3 months after the last dose of study medication?                          | Y | N |

**C. EXCLUSION CRITERIA**

- |   |   |   |
|---|---|---|
| 1. Subject has complicating medical issues that in the opinion of the investigator would interfere with the trial?                      | Y | N |
| 2. Subject has had any live vaccinations in the preceding three months (90 days)?   | Y | N |
| 3. Subject requires chronic use of systemic steroids or other immunosuppressive agents for other conditions?                            | Y | N |
| 4. Subject has active EBV infection (EBV seronegative and EBV PCR positive)?  | Y | N |
| 5. Subject has current or past serologic evidence of Hepatitis B or C, or HIV infection?  | Y | N |
| 6. Subject has abnormal laboratory tests that in the opinion of the investigator would preclude participation in the trial?             | Y | N |
| 7. Subject has a positive PPD test result?  | Y | N |
| 8. Subject is taking any non-insulin medications that affect glucose homeostasis?   | Y | N |
| 9. Subject is currently participating in another type 1 diabetes treatment study?   | Y | N |
| <i>If FEMALE, answer the following questions (10-15):</i>   |   |   |
| 10. Subject is sexually active and refuses to use an effective form of birth control?   | Y | N |
| 11. Subject has reproductive potential and refuses to undergo pregnancy testing during the course of the study?                         | Y | N |
| 12. Subject has reproductive potential and refuses to promptly report possible or confirmed pregnancies during the course of the study? | Y | N |
| 13. Subject is currently pregnant or less than three months postpartum?   | Y | N |
| 14. Subject anticipates becoming pregnant during the study?   | Y | N |
| 15. Subject refused or did not complete the pregnancy test at this visit?   | Y | N |

*On all questions write "?" if the desired information is currently unavailable, but is being checked and will be known in future updates. Write "\*" if the desired information is permanently unavailable (i.e. will not be known in any future updates).*

Site Number:

Screening ID:  -

Participant Letters:

**STOP AND DOUBLE CHECK ELIGIBILITY**

Double check Sections B and C. To proceed, you must have:

Answered YES to *every* question in Section B

AND Answered NO to *every* question in Section C

If NOT eligible, **STOP, do not continue with any further assessments.** Send the top copy of this form to the TrialNet Coordinating Center.

**Initials (first, middle, last) of person completing this form:**

F M L

**Date form completed:**

/  /   
DAY MONTH YEAR

*On all questions write “?” if the desired information is currently unavailable, but is being checked and will be known in future updates. Write “\*” if the desired information is permanently unavailable (i.e. will not be known in any future updates).*